Description of Invention:
Expression of the HIV-1 Vif protein in the absence of other viral factors such a Tat and Rev is extremely inefficient due to the presence of inhibitory sequences on its mRNA. This invention uses codon optimization to remove such inhibitory sequences without altering the amino acid sequence of the protein. The modified vif gene in the resulting pcDNA -hVIF vector is expressed under the control of the CMV promoter. In this, the protein functions as wild type and is more amendable to high-level expression in mammalian cells.
Currently this vector is used in on-going studies of HIV infection and its ability to overcome cellular restriction to replication. As such, the reagent will be valuable to other researchers in discovering mechanisms of replication, next generation therapeutics and potentially prevention of infection as well.
Inventors:
Klaus Strebel (NIAID) Stephan Bour (NIAID) Kim-Lien Nguyen (NIAID)
Patent Status:
DHHS Reference No. E-041-2004/0 -- Research Tool/Biological Material
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
